vs
Side-by-side financial comparison of CRISPR Therapeutics AG (CRSP) and Prime Medicine, Inc. (PRME). Click either name above to swap in a different company.
CRISPR Therapeutics AG is the larger business by last-quarter revenue ($35.7M vs $838.0K, roughly 42.6× Prime Medicine, Inc.). CRISPR Therapeutics AG runs the higher net margin — -104.5% vs -5498.7%, a 5394.1% gap on every dollar of revenue. On growth, Prime Medicine, Inc. posted the faster year-over-year revenue change (-61.6% vs -82.3%). Prime Medicine, Inc. produced more free cash flow last quarter ($-37.5M vs $-50.3M).
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. I...
Prime Medicine, Inc. is an American biotechnology company developing gene therapies based on prime editing. The company is headquartered in Cambridge, Massachusetts.
CRSP vs PRME — Head-to-Head
Income Statement — Q4 FY2024 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $35.7M | $838.0K |
| Net Profit | $-37.3M | $-46.1M |
| Gross Margin | — | — |
| Operating Margin | -181.0% | -5800.5% |
| Net Margin | -104.5% | -5498.7% |
| Revenue YoY | -82.3% | -61.6% |
| Net Profit YoY | -141.8% | -9.0% |
| EPS (diluted) | $-0.41 | $-0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $838.0K | ||
| Q3 25 | — | $1.2M | ||
| Q2 25 | — | $1.1M | ||
| Q1 25 | — | $1.5M | ||
| Q4 24 | $35.7M | $2.2M | ||
| Q2 24 | — | $0 | ||
| Q1 24 | — | $591.0K | ||
| Q4 23 | $201.2M | $0 |
| Q4 25 | — | $-46.1M | ||
| Q3 25 | — | $-50.6M | ||
| Q2 25 | — | $-52.6M | ||
| Q1 25 | — | $-51.9M | ||
| Q4 24 | $-37.3M | $-42.3M | ||
| Q2 24 | — | $-55.3M | ||
| Q1 24 | — | $-45.8M | ||
| Q4 23 | $89.3M | $-65.6M |
| Q4 25 | — | -5800.5% | ||
| Q3 25 | — | -4406.0% | ||
| Q2 25 | — | -4787.2% | ||
| Q1 25 | — | -3603.3% | ||
| Q4 24 | -181.0% | -2025.7% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -8179.5% | ||
| Q4 23 | 34.6% | — |
| Q4 25 | — | -5498.7% | ||
| Q3 25 | — | -4129.1% | ||
| Q2 25 | — | -4716.7% | ||
| Q1 25 | — | -3568.8% | ||
| Q4 24 | -104.5% | -1936.6% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -7743.0% | ||
| Q4 23 | 44.4% | — |
| Q4 25 | — | $-0.22 | ||
| Q3 25 | — | $-0.32 | ||
| Q2 25 | — | $-0.41 | ||
| Q1 25 | — | $-0.40 | ||
| Q4 24 | $-0.41 | $-0.31 | ||
| Q2 24 | — | $-0.46 | ||
| Q1 24 | — | $-0.44 | ||
| Q4 23 | $1.12 | $-0.72 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.9B | $63.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.9B | $120.9M |
| Total Assets | $2.2B | $342.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $63.0M | ||
| Q3 25 | — | $71.4M | ||
| Q2 25 | — | $53.8M | ||
| Q1 25 | — | $91.9M | ||
| Q4 24 | $1.9B | $182.5M | ||
| Q2 24 | — | $55.6M | ||
| Q1 24 | — | $94.2M | ||
| Q4 23 | $1.7B | $41.6M |
| Q4 25 | — | $120.9M | ||
| Q3 25 | — | $161.8M | ||
| Q2 25 | — | $60.9M | ||
| Q1 25 | — | $106.9M | ||
| Q4 24 | $1.9B | $153.1M | ||
| Q2 24 | — | $196.6M | ||
| Q1 24 | — | $243.8M | ||
| Q4 23 | $1.9B | $133.1M |
| Q4 25 | — | $342.7M | ||
| Q3 25 | — | $385.0M | ||
| Q2 25 | — | $279.0M | ||
| Q1 25 | — | $328.2M | ||
| Q4 24 | $2.2B | $297.5M | ||
| Q2 24 | — | $259.7M | ||
| Q1 24 | — | $311.4M | ||
| Q4 23 | $2.2B | $193.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-50.0M | $-37.3M |
| Free Cash FlowOCF − Capex | $-50.3M | $-37.5M |
| FCF MarginFCF / Revenue | -140.9% | -4480.4% |
| Capex IntensityCapex / Revenue | 0.7% | 34.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-325.9M | $-167.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-37.3M | ||
| Q3 25 | — | $-35.0M | ||
| Q2 25 | — | $-41.4M | ||
| Q1 25 | — | $-48.9M | ||
| Q4 24 | $-50.0M | $16.2M | ||
| Q2 24 | — | $-45.5M | ||
| Q1 24 | — | $-67.7M | ||
| Q4 23 | $-96.1M | $-43.9M |
| Q4 25 | — | $-37.5M | ||
| Q3 25 | — | $-35.3M | ||
| Q2 25 | — | $-43.0M | ||
| Q1 25 | — | $-51.3M | ||
| Q4 24 | $-50.3M | $14.5M | ||
| Q2 24 | — | $-47.4M | ||
| Q1 24 | — | $-70.0M | ||
| Q4 23 | $-96.8M | $-45.7M |
| Q4 25 | — | -4480.4% | ||
| Q3 25 | — | -2880.5% | ||
| Q2 25 | — | -3855.1% | ||
| Q1 25 | — | -3526.8% | ||
| Q4 24 | -140.9% | 662.1% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -11849.6% | ||
| Q4 23 | -48.1% | — |
| Q4 25 | — | 34.6% | ||
| Q3 25 | — | 20.2% | ||
| Q2 25 | — | 141.0% | ||
| Q1 25 | — | 166.6% | ||
| Q4 24 | 0.7% | 82.0% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 393.2% | ||
| Q4 23 | 0.4% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | -1.08× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CRSP
| Collaboration Revenue | $35.0M | 98% |
| Grant | $2.3M | 6% |
PRME
Segment breakdown not available.
